{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:33:10Z","timestamp":1782977590635,"version":"3.54.5"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60134-4","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:27:35Z","timestamp":1748327255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-2659","authenticated-orcid":false,"given":"Thomas","family":"Dal Maso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-004X","authenticated-orcid":false,"given":"Chiara","family":"Sinisgalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Zilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Franzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Tessari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Pardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3825-874X","authenticated-orcid":false,"given":"Jan","family":"Steyaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-1641","authenticated-orcid":false,"given":"Steven","family":"Ballet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-3598","authenticated-orcid":false,"given":"Elisa","family":"Greggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-696X","authenticated-orcid":false,"given":"Wim","family":"Vers\u00e9es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-8705","authenticated-orcid":false,"given":"Nicoletta","family":"Plotegher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"60134_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1194\/jlr.M064923","volume":"57","author":"ARA Marques","year":"2016","unstructured":"Marques, A. R. A. et al. Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular \u03b2-glucosidases. J. Lipid Res. 57, 451\u2013463 (2016).","journal-title":"J. Lipid Res."},{"key":"60134_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski, G. A. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet 372, 1263\u20131271 (2008).","journal-title":"Lancet"},{"key":"60134_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"60134_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin, E. C., Ryan, E. & Sidransky, E. Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol. Genet. Metab. 132, 49\u201358 (2021).","journal-title":"Mol. Genet. Metab."},{"key":"60134_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/diseases5010010","volume":"5","author":"T Roshan Lal","year":"2017","unstructured":"Roshan Lal, T. & Sidransky, E. The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases 5, 10 (2017).","journal-title":"Diseases"},{"key":"60134_CR6","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms23105842","volume":"23","author":"ML Furderer","year":"2022","unstructured":"Furderer, M. L., Hertz, E., Lopez, G. J. & Sidransky, E. Neuropathological features of Gaucher disease and Gaucher disease with Parkinsonism. Int. J. Mol. Sci. 23, 5842 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"60134_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"60134_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"60134_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","volume":"69","author":"LN Clark","year":"2007","unstructured":"Clark, L. N. et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69, 1270\u20131277 (2007).","journal-title":"Neurology"},{"key":"60134_CR10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker, T. B. et al. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 91, 695\u2013702 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"60134_CR11","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1111\/febs.16758","volume":"290","author":"S Pokorna","year":"2023","unstructured":"Pokorna, S. et al. Design of a stable human acid-\u03b2-glucosidase: towards improved Gaucher disease therapy and mutation classification. FEBS J. 290, 3383\u20133399 (2023).","journal-title":"FEBS J."},{"key":"60134_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek, D. et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of \u03b2-glucocerebrosidase. Cell 131, 770\u2013783 (2007).","journal-title":"Cell"},{"key":"60134_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJR Fernandes","year":"2016","unstructured":"Fernandes, H. J. R. et al. ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Rep. 6, 342\u2013356 (2016).","journal-title":"Stem Cell Rep."},{"key":"60134_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ejhg.2013.182","volume":"22","author":"E Malini","year":"2014","unstructured":"Malini, E. et al. Functional analysis of 11 novel GBA alleles. Eur. J. Hum. Genet. 22, 511\u2013516 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"60134_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","volume":"298","author":"L Smith","year":"2017","unstructured":"Smith, L., Mullin, S. & Schapira, A. H. V. Insights into the structural biology of Gaucher disease. Exp. Neurol. 298, 180\u2013190 (2017).","journal-title":"Exp. Neurol."},{"key":"60134_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame, L. D. et al. Mitochondria and quality control defects in a mouse model of Gaucher disease - Links to parkinson\u2019s disease. Cell Metab. 17, 941\u2013953 (2013).","journal-title":"Cell Metab."},{"key":"60134_CR17","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41418-019-0442-2","volume":"27","author":"N Plotegher","year":"2020","unstructured":"Plotegher, N. et al. Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload. Cell Death Differ. 27, 1588\u20131603 (2020).","journal-title":"Cell Death Differ."},{"key":"60134_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo, S. H. et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by blockade of chaperone-mediated autophagy. Sci. Adv. 8, 1\u201320 (2022).","journal-title":"Sci. Adv."},{"key":"60134_CR19","doi-asserted-by":"publisher","unstructured":"Smith, L. & Schapira, A. H. V. GBA variants and Parkinson disease: mechanisms and treatments. Cells 11. https:\/\/doi.org\/10.1038\/nrneurol.2010.216 (2022).","DOI":"10.1038\/nrneurol.2010.216"},{"key":"60134_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455\u2013463 (2012).","journal-title":"Ann. Neurol."},{"key":"60134_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085\u20131089 (2015).","journal-title":"Mov. Disord."},{"key":"60134_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi, N. et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 22, 661\u2013671 (2023).","journal-title":"Lancet Neurol."},{"key":"60134_CR23","doi-asserted-by":"publisher","first-page":"13813","DOI":"10.1073\/pnas.0605928103","volume":"103","author":"RA Steet","year":"2006","unstructured":"Steet, R. A. et al. The iminosugar isofagomine increases the activity of N370S mutant acid \u03b2-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. USA 103, 13813\u201313818 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR24","doi-asserted-by":"publisher","first-page":"11696","DOI":"10.1002\/anie.201505147","volume":"54","author":"T Mena-Barrag\u00e1n","year":"2015","unstructured":"Mena-Barrag\u00e1n, T. et al. PH-Responsive pharmacological chaperones for rescuing mutant glycosidases. Angew. Chem. - Int Ed. 54, 11696\u201311700 (2015).","journal-title":"Angew. Chem. - Int Ed."},{"key":"60134_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cmdc.201700050","volume":"12","author":"A Sev\u0161ek","year":"2017","unstructured":"Sev\u0161ek, A. et al. N-guanidino derivatives of 1, 5-dideoxy-1, 5-imino-d-xylitol are Potent, Selective, and Stable Inhibitors of \u03b2-Glucocerebrosidase. ChemMedChem 12, 483\u2013486 (2017).","journal-title":"ChemMedChem"},{"key":"60134_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbic.202300730","volume":"25","author":"MG Davighi","year":"2024","unstructured":"Davighi, M. G. et al. pH-Responsive Trihydroxylated Piperidines Rescue The Glucocerebrosidase Activity in Human Fibroblasts Bearing The Neuronopathic Gaucher-Related L444P\/L444P Mutations in GBA1 Gene. ChemBioChem 25, 1\u201312 (2024).","journal-title":"ChemBioChem"},{"key":"60134_CR27","doi-asserted-by":"publisher","first-page":"13192","DOI":"10.1073\/pnas.0705637104","volume":"104","author":"W Zheng","year":"2007","unstructured":"Zheng, W. et al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. USA 104, 13192\u201313197 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR28","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1021\/jacs.7b13003","volume":"140","author":"J Zheng","year":"2018","unstructured":"Zheng, J. et al. \u03b2-Glucocerebrosidase modulators promote dimerization of \u03b2-glucocerebrosidase and reveal an allosteric binding site. J. Am. Chem. Soc. 140, 5914\u20135924 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"60134_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"60134_CR30","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1021\/jm300063b","volume":"55","author":"S Patnaik","year":"2012","unstructured":"Patnaik, S. et al. Discovery, structure - Activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med Chem. 55, 5734\u20135748 (2012).","journal-title":"J. Med Chem."},{"key":"60134_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/syn.21967","volume":"71","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards, A., Ko, W. K. D., Li, Q., Bezard, E. & Schapira, A. H. V. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse 71, 17\u201319 (2017).","journal-title":"Synapse"},{"key":"60134_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards, A., Daly, L., Bezard, E. & Schapira, A. H. V. Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann. Neurol. 80, 766\u2013775 (2016).","journal-title":"Ann. Neurol."},{"key":"60134_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill, A. et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481\u20131495 (2014).","journal-title":"Brain"},{"key":"60134_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","volume":"84","author":"AE Kopytova","year":"2021","unstructured":"Kopytova, A. E. et al. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Park Relat. Disord. 84, 112\u2013121 (2021).","journal-title":"Park Relat. Disord."},{"key":"60134_CR35","doi-asserted-by":"publisher","unstructured":"Pantoom, S. et al. Mechanistic insight into the mode of action of acid \u03b2-glucosidase enhancer ambroxol. Int. J. Mol. Sci. 23. https:\/\/doi.org\/10.3390\/ijms23073536 (2022).","DOI":"10.3390\/ijms23073536"},{"key":"60134_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"60134_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska, I. & Muyldermans, S. The therapeutic potential of nanobodies. BioDrugs 34, 11\u201326 (2020).","journal-title":"BioDrugs"},{"key":"60134_CR38","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.0505379103","volume":"103","author":"E De Genst","year":"2006","unstructured":"De Genst, E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. USA 103, 4586\u20134591 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.64922","volume":"9","author":"J Paesmans","year":"2020","unstructured":"Paesmans, J. et al. A structure of substrate-bound synaptojanin1 provides new insights in its mechanism and the effect of disease mutations. Elife 9, 1\u201327 (2020).","journal-title":"Elife"},{"key":"60134_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.sbi.2011.06.011","volume":"21","author":"J Steyaert","year":"2011","unstructured":"Steyaert, J. & Kobilka, B. K. Nanobody stabilization of G protein-coupled receptor conformational states. Curr. Opin. Struct. Biol. 21, 567\u2013572 (2011).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"60134_CR41","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1111\/febs.16376","volume":"289","author":"I Hmila","year":"2022","unstructured":"Hmila, I. et al. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 289, 4657\u20134673 (2022).","journal-title":"FEBS J."},{"key":"60134_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature24645","volume":"552","author":"AF Schubert","year":"2017","unstructured":"Schubert, A. F. et al. Structure of PINK1 in complex with its substrate ubiquitin. Nature 552, 51\u201356 (2017).","journal-title":"Nature"},{"key":"60134_CR43","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1107\/S0907444906038303","volume":"62","author":"B Brumshtein","year":"2006","unstructured":"Brumshtein, B., Wormald, M. R., Silman, I., Futerman, A. H. & Sussman, J. L. Structural comparison of differently glycosylated forms of acid-\u03b2-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr Sect. D. Biol. Crystallogr 62, 1458\u20131465 (2006).","journal-title":"Acta Crystallogr Sect. D. Biol. Crystallogr"},{"key":"60134_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1358\/dot.2011.47.7.1608922","volume":"47","author":"A Zimran","year":"2011","unstructured":"Zimran, A. Velaglucerase alfa: a new option for Gaucher disease treatment. Drugs Today 47, 515\u2013529 (2011).","journal-title":"Drugs Today"},{"key":"60134_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1042\/BSR20130081","volume":"33","author":"Y Tekoah","year":"2013","unstructured":"Tekoah, Y. et al. Glycosylation and functionality of recombinant \u03b2-glucocerebrosidase from various production systems. Biosci. Rep. 33, 771\u2013781 (2013).","journal-title":"Biosci. Rep."},{"key":"60134_CR46","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","volume":"16","author":"AD Klein","year":"2016","unstructured":"Klein, A. D. et al. Identification of modifier genes in a mouse model of Gaucher disease. Cell Rep. 16, 2546\u20132553 (2016).","journal-title":"Cell Rep."},{"key":"60134_CR47","doi-asserted-by":"publisher","unstructured":"Kedariti, M. et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. npj Park. Dis. 8. https:\/\/doi.org\/10.1038\/s41531-022-00354-3 (2022).","DOI":"10.1038\/s41531-022-00354-3"},{"key":"60134_CR48","doi-asserted-by":"publisher","unstructured":"Sanchez-Martinez, A. et al. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci. Rep. 6. https:\/\/doi.org\/10.1038\/srep31380 (2016).","DOI":"10.1038\/srep31380"},{"key":"60134_CR49","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138, 2648\u20132658 (2015).","journal-title":"Brain"},{"key":"60134_CR50","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GHB Maegawa","year":"2009","unstructured":"Maegawa, G. H. B. et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502\u201323516 (2009).","journal-title":"J. Biol. Chem."},{"key":"60134_CR51","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3390\/molecules25143145","volume":"25","author":"ML Tran","year":"2020","unstructured":"Tran, M. L., G\u00e9nisson, Y., Ballereau, S. & Dehoux, C. Second-generation pharmacological chaperones: beyond inhibitors. Molecules 25, 3145 (2020).","journal-title":"Molecules"},{"key":"60134_CR52","first-page":"389","volume":"13","author":"R Zhang","year":"2010","unstructured":"Zhang, R. & Monsma, F. Fluorescence-based thermal shift assays. Curr. Opin. Drug Discov. Devel.13, 389\u2013402 (2010).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"60134_CR53","doi-asserted-by":"publisher","unstructured":"Kim, M. J., Kim, S., Reinheckel, T. & Krainc, D. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase. JCI Insight 9. https:\/\/doi.org\/10.1172\/jci.insight.169594 (2024).","DOI":"10.1172\/jci.insight.169594"},{"key":"60134_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/glycob\/cwp138","volume":"20","author":"B Brumshtein","year":"2010","unstructured":"Brumshtein, B. et al. Characterization of gene-activated human acid-\u03b2-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20, 24\u201332 (2010).","journal-title":"Glycobiology"},{"key":"60134_CR55","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.embor.embor873","volume":"4","author":"H Dvir","year":"2003","unstructured":"Dvir, H. et al. X-ray structure of human acid-\u03b2-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4, 704\u2013709 (2003).","journal-title":"EMBO Rep."},{"key":"60134_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nchembio850","volume":"3","author":"RL Lieberman","year":"2007","unstructured":"Lieberman, R. L. et al. Structure of acid \u03b2-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat. Chem. Biol. 3, 101\u2013107 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"60134_CR57","doi-asserted-by":"publisher","unstructured":"Lieberman, R. L. A guided tour of the structural biology of Gaucher disease: acid-\u03b2-glucosidase and saposin C. Enzyme Res. 2011, https:\/\/doi.org\/10.4061\/2011\/973231 (2011).","DOI":"10.4061\/2011\/973231"},{"key":"60134_CR58","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1073\/pnas.1818411116","volume":"116","author":"R Romero","year":"2019","unstructured":"Romero, R. et al. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Proc. Natl. Acad. Sci. USA 116, 5086\u20135095 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nn.3637","volume":"17","author":"X Fan","year":"2014","unstructured":"Fan, X., Jin, W. Y., Lu, J., Wang, J. & Wang, Y. T. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat. Neurosci. 17, 471\u2013480 (2014).","journal-title":"Nat. Neurosci."},{"key":"60134_CR60","unstructured":"Lodish, H. et al. Section 17.4 Translocation of secretory proteins across the ER membrane. In Molecular Cell Biology 4th edn, W. H. Freeman and Company (2000)."},{"key":"60134_CR61","doi-asserted-by":"crossref","unstructured":"Singh, B. & Bhaskar, S. Methods for detection of autophagy in mammalian cells. In Stem Cells and Aging. Methods in Molecular Biology, Vol. 2045, (Humana, New York, NY, 2018).","DOI":"10.1007\/7651_2018_190"},{"key":"60134_CR62","doi-asserted-by":"publisher","unstructured":"Navarro-Romero, A. et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. npj Park. Dis. 8, https:\/\/doi.org\/10.1038\/s41531-022-00397-6 (2022).","DOI":"10.1038\/s41531-022-00397-6"},{"key":"60134_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1074\/jbc.M110.150433","volume":"286","author":"RR Wei","year":"2011","unstructured":"Wei, R. R. et al. X-ray and biochemical analysis of N370S mutant human acid \u03b2-glucosidase. J. Biol. Chem. 286, 299\u2013308 (2011).","journal-title":"J. Biol. Chem."},{"key":"60134_CR64","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2015","unstructured":"Magalhaes, J. et al. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum. Mol. Genet 25, 3432\u20133445 (2015).","journal-title":"Hum. Mol. Genet"},{"key":"60134_CR65","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1523\/JNEUROSCI.4527-15.2016","volume":"36","author":"KJ Kinghorn","year":"2016","unstructured":"Kinghorn, K. J. et al. A Drosophila model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by rapamycin. J. Neurosci. 36, 11654\u201311670 (2016).","journal-title":"J. Neurosci."},{"key":"60134_CR66","doi-asserted-by":"crossref","unstructured":"Compain, P. & Martin, O. R. Iminosugars: From Synthesis to Therapeutic Applications. (John Wiley & Sons, Ltd, 2007).","DOI":"10.1002\/9780470517437"},{"key":"60134_CR67","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1039\/C6CC01564F","volume":"52","author":"EM S\u00e1nchez-Fern\u00e1ndez","year":"2016","unstructured":"S\u00e1nchez-Fern\u00e1ndez, E. M., Garc\u00eda Fern\u00e1ndez, J. M. & Ortiz Mellet, C. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem. Commun. 52, 5497\u20135515 (2016).","journal-title":"Chem. Commun."},{"key":"60134_CR68","doi-asserted-by":"crossref","unstructured":"Benito, J., Garc\u00eda Fern\u00e1ndez, J. & Ortiz Mellet, C. Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin. Ther. Pat. 21, 885\u2013903 (2011).","DOI":"10.1517\/13543776.2011.569162"},{"key":"60134_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4155\/fmc.13.14","volume":"5","author":"A Trapero","year":"2013","unstructured":"Trapero, A. & Llebaria, A. Glucocerebrosidase inhibitors for the treatment of Gaucher disease. Future Med. Chem. 5, 573\u2013590 (2013).","journal-title":"Future Med. Chem."},{"key":"60134_CR70","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Bail\u00e9n, M., Clemente, F., Matassini, C. & Cardona, F. GCase enhancers: a potential therapeutic option for Gaucher disease and other neurological disorders. Pharmaceuticals 15, https:\/\/doi.org\/10.3390\/ph15070823 (2022).","DOI":"10.3390\/ph15070823"},{"key":"60134_CR71","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1002\/anie.202013890","volume":"60","author":"J Benz","year":"2021","unstructured":"Benz, J. et al. Novel \u03b2-glucocerebrosidase activators that bind to a new pocket at a dimer interface and induce dimerization. Angew. Chem. - Int Ed. 60, 5436\u20135442 (2021).","journal-title":"Angew. Chem. - Int Ed."},{"key":"60134_CR72","doi-asserted-by":"publisher","first-page":"11168","DOI":"10.1021\/acs.jmedchem.4c00702","volume":"67","author":"N Palmer","year":"2024","unstructured":"Palmer, N. et al. Fragment-based discovery of a series of allosteric-binding site modulators of \u03b2-glucocerebrosidase. J. Med Chem. 67, 11168\u201311181 (2024).","journal-title":"J. Med Chem."},{"key":"60134_CR73","first-page":"1","volume":"19","author":"MED Schulze","year":"2024","unstructured":"Schulze, M. E. D. et al. Identification of \u00df-Glucocerebrosidase Activators for Glucosylceramide hydrolysis. ChemMedChem 19, 1\u201310 (2024).","journal-title":"ChemMedChem"},{"key":"60134_CR74","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1073\/pnas.1514005113","volume":"113","author":"F Zunke","year":"2016","unstructured":"Zunke, F. et al. Characterization of the complex formed by \u03b2-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proc. Natl. Acad. Sci. USA 113, 3791\u20133796 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR75","doi-asserted-by":"crossref","unstructured":"Dobert, J. P. et al. Cryo-TEM structure of \u03b2-glucocerebrosidase in complex with its transporter LIMP-2. Nat. Commun. 6, 3074 (2025).","DOI":"10.21203\/rs.3.rs-4330358\/v1"},{"key":"60134_CR76","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1432-1033.1987.tb11008.x","volume":"164","author":"LM JONSSON","year":"1987","unstructured":"JONSSON, L. M. et al. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur. J. Biochem 164, 171\u2013179 (1987).","journal-title":"Eur. J. Biochem"},{"key":"60134_CR77","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1194\/jlr.RA119000154","volume":"60","author":"LT Lelieveld","year":"2019","unstructured":"Lelieveld, L. T. et al. Role of \u03b2-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. J. Lipid Res. 60, 1851\u20131867 (2019).","journal-title":"J. Lipid Res."},{"key":"60134_CR78","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106\u2013115 (2022).","journal-title":"Nat. Neurosci."},{"key":"60134_CR79","doi-asserted-by":"publisher","unstructured":"van der Koog, L., Gandek, T. B. & Nagelkerke, A. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv. Healthc. Mater. 11, https:\/\/doi.org\/10.1002\/adhm.202100639 (2022).","DOI":"10.1002\/adhm.202100639"},{"key":"60134_CR80","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2014.039","volume":"9","author":"E Pardon","year":"2014","unstructured":"Pardon, E. et al. A general protocol for the generation of Nanobodies for structural biology. Nat. Protoc. 9, 674\u2013693 (2014).","journal-title":"Nat. Protoc."},{"key":"60134_CR81","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cmmi.1696","volume":"11","author":"S Massa","year":"2016","unstructured":"Massa, S. et al. Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media Mol. Imaging 11, 328\u2013339 (2016).","journal-title":"Contrast Media Mol. Imaging"},{"key":"60134_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2112712119","volume":"119","author":"RK Singh","year":"2022","unstructured":"Singh, R. K., et al. Nanobodies as allosteric modulators of Parkinson\u2019s disease-associated LRRK2. Proc. Natl. Acad. Sci. USA 119, 1\u201334 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60134_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"60134_CR84","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. Sect. D. Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"60134_CR85","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"60134_CR86","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.5334\/ojb.ab","volume":"1","author":"M Filocamo","year":"2014","unstructured":"Filocamo, M. et al. Cell line and DNA biobank from patients affected by Genetic diseases. Open J. Bioresour. 1, e2 (2014).","journal-title":"Open J. Bioresour."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60134-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60134-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60134-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:02:51Z","timestamp":1748372571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60134-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60134"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60134-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. D. M, W.V., N. P., E. G., and C. S. are inventors on a filed patent application covering findings described in this manuscript (International application number: PCT\/EP2025\/055198). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4890"}}